Prevention of pneumococcal disease: An update on the Belgian consensus report

Acta Clinica Belgica

Volumn 54, Issue 6, 1999, Pages 321-327

  Peleman, R A ^a   Peetermans, W E ^b   Van Laethem, Y ^b   Bachez, P G ^b   Vanatoru, J ^b   Van Wassenhove, K ^b   Struelens, M J ^b   Verhaegen, J L ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

BELGIUM; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; REVIEW; STREPTOCOCCUS INFECTION; VACCINATION;

EID: 0033395195     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1080/17843286.1999.11754255     Document Type: Review

References (44)

1. Peetermans W, Bachez P, Peleman R. et al. Belgian Consensus on Pneumococcal Vaccine. Acta Clin Belg 1996; 51: 350-356.
2. Obarro SK, Monteil MA, Henderson DC. The pneumococcal problem. Br Med J 1996; 312: 1521-5.
3. Fedson DS, Anthony J, Scott G. The burden of pneumococcal disease among adults in developed and developing countries: What is and is not known. Vaccine 1999; 17: S11-18.
4. rd ed. Plotkin SA, Mortimer EA eds. Philadelphia; WB Saunders 1999; 553-607.
5. Shapiro ED, Berg AT, Austrian R et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. New Engl J Med 1991; 325: 1453-1460.
6. Spanjaard L, van der Ende A, Schuerman I, Dankert J. Is de incidentie van sepsis en meningitis door Streptococcus pneumoniae in Nederland toegenomen? Inf Bull 1998; 9: 221-3.
7. Nationaal Referentielaboratorium voor Pneumokokken. Surveillance van de pneumokokkeninfecties in België. Verslag voor 1998.
8. Lagrou K, Van Eldere J, Verhaegen J, Peetermans WE. Macrolide resistance phenotypes and genotypes in clinical Streptococcus pneumoniae isolates. Berlin, ECCMID 1999, Abstract P 0067.
9. Vanhoof R, Carpentier M, Glupezynski Y et al. Surveillance of pneumococcal resistance in Belgium during winter 1996-1997. Acta Clin Belg 1998; 53: 275-281.
10. Hoefnagels-Schuermans A, Van Eldere J, Van Lierde S, Verbist L, Verhaegen J, Peetermans WE. Increase in penicillin resistance rates in Belgium due to clonal spread of a penicillin-resistant 23F Streptococcus pneumoniae strain. Eur J Clin Microbiol lnfect Dis 1999; 18: 120-125.
11. Geslin P, Spicq C, Georges S, Sissia G, Fremaux A. Sensibilité au céfotaxime de 4965 souches de pneumocoque isolées en France durant l'année 1995. Méd Mal Infect 1997; 27: 833-837.
12. Koivula I, Stén M, Leinonen M, Mäkelä PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997; 103: 281-290.
13. Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine 1999; 17: S91-93.
14. Popp W, Rosenberger-Spitzy A.. Efficacy of pneumococcal vacciantion in geriatric patients. Am J Respir Crit Care Med 1998; 157: A168.
15. Ortqvist A, Hedlund J, Burman L-A, Elbel E, Höfer M, Leinonen M, Lindblad I, Sundelöd B, Kallin M. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. The Lancet 1998; 351: 399-403.
16. Nuorti JP, Butler JC, Crutcher JM, Guevara R, Welch D, Holder P, Elliott JA. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. New Engl J Med 1998; 338: 1861-1868.
17. Lombaert G, De Graeve D, Goossens H. Een economische evaluatie van het pneumokokkenvaccin voor België. Rapport 97/342, 1997.
18. Baltussen RMPM, Ament AJHA, Leidl RM, van Furth R. Cost-effectivenees of vaccination against pneumococcal pneumonia in The Netherlands. Eur J Public Health 1997; 7: 153-161.
19. Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997; 278: 1333-1339.
20. Sankilampi U, Honkanen PO, Pyhälä R, Leinonen M. Associations of prevaccination antibody levels with adverse reactions to pneumococcal and influenza vaccines administered simultaneously in the elderly. Vaccine 1997; 15: 1133-37.
21. Jackson L, Benson P, Sneller VP et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999; 281: 243-248.
22. Petrasch S, Kuhnemund O, Reinacher A. et al. Antibody responses of splenectomized patients with non-Hodgkin's lymphoma to immunization with polyvalent pneumococcal vaccines. Clin Diagn Lab Immunol 1997; 4: 635-638.
23. Mobrine DC, Siber GR, Samra Y et al. Normal IgG and impaired IgM responses to polysaccharide vaccines in asplenic patients. J Infect Dis 1999; 179: 513-7.
24. Shatz DV, Schinsky MF, Pais LB, Romero-Steiner S, Kirton OC, Carole GM. Immune responses of splectmized trauma patients to the 23-valent pneumococcal polysaccharide vaccine at 1 versus 7 versus 14 days after splenectomy. J Trauma 1998; 44: 760-5.
25. Dengler TJ, Strnad N, Zimmerman R et al. Pneumococcal immunisation after heart and lung transplantation: immune response in immune-suppressed patients and in healthy controls. Deutsche Med Wschr 1996; 121: 1519-1525.
26. Dengler TJ, Strnad N, Bühring I et al. Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation. Transplantation 1998; 66: 1340-1347.
27. Rubins JB, Puri AKG, Loch J et al. Magnitude, duration, quality and function of pneumococcal vaccine responses in elderly adults. J Infect Dis 1998; 178: 431-440.
28. Musher DM, Groover JE, Graviss EA, Baughn RE. The lact of association between aging and postvaccination levels of IgG antibody to capsular polysaccharides of Streptococcus pneumoniae. Clin Infect Dis 1996; 22: 165-167.
29. Sankilampi U, Honkanen PO, Bloigu A, Leinonen M. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1997; 176: 1100-4.
30. Poland GA. The burden of pneumococcal disease: the role of conjugatec vaccines. Vaccine 1999; 17: 1674-79.
31. Nieminen T, Eskola J, Kayhty H. Pneumococcal conjugate vaccination in adults: circulating antibody secreting cell response and humoral antibody responses in saliva and in serum. Vaccine 1998; 16: 630-6.
32. Dagan R, Melamed R, Muallem M et al. Reduction of nasopharyngeal carriage of Pneumococci during the second year of live by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996; 174: 1271-8.
33. th ICAAC, San Diego, Abstract LB9.
34. Dagan R, Melamed R, Zamir O, Leroy O. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23 F polysaccharides conjugated to either tetanus toxoid or diphteria toxoid in young infants and their boosterability by native polysaccharide antigens. Ped Infect Dis 1997; 16: 1053-9.31.
35. Breukels MA, Rijkers GT, Voorhorst-Ogink, Zegers, BJM, Sanders LAM. Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta. J Infect Dis 1999; 179: 1152-1156.
36. Mc Donald P, Friedman EHI, Banks A, Anderson R, Carman. Pneumococcal vaccine campaign based in general practice. Br Med J 1997; 314: 1094-8.
37. Honkanen PO, Keistinen T, Kivelä SA. The impact of vaccination strategy and methods of information on influenza and pneumococcal vaccination coverage in the elderly population. Vaccine 1997; 15: 317-320.
38. Govaert ME, Thijs CTMCN, Masurel N, Sprenger MJW, Dinant GK, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. JAMA 1994; 272: 1661-6.
39. Noe CA, Markson LJ. Pneumococcal vaccination: perception of primary care physicians. Prev Med 1998; 27: 767-772.
40. Fedson D. Pneumococcal vaccination in the US and 20 other developed countries 1981-1996. Clin Infec Dis 1998; 26: 1117-23.
41. Advisory Committe on Immunisation Practices. Prevention of pneumococcal disease. MMWR 1997; 46(RR8): 1-24.
42. Anonymous. Impfempfehlungen der Ständigen Impfkommission am Robert Koch-Institut. Epidem Bull 1998; 15: 101-112.
43. Peetermans WE, Lacante P. Pneumococcal vaccination by general practitioners: an evaluation of current practice. Submitted.
44. Watkins J. Pneumococcal vaccination use by UK doctors. First International Symposium on Pneumococci and Pneumococcal Diseases. Elsinore 1998. Abstract p. 128.